News and reporting on cancer immunotherapy.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.
The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.